NAS
XENE icon

Nykredit A/S’s Xenon Pharmaceuticals XENE Stock Holding History

Nykredit A/S’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.5K Buy
+1,102
New +$61.2K ﹤0.01% 1431

Other funds holding XENE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Nykredit A/S's XENE Position: Q2 2026 in Review

Nykredit A/S opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 1,102 shares worth $66.5K. The stake represents ﹤0.01% of the portfolio and ranks #1431 among its holdings.

196 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Nykredit A/S held 1,102 shares of Xenon Pharmaceuticals worth $66.5K as of Q2 2026.
  • Xenon Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
  • Xenon Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1431 holding.
  • 196 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.